Deutetrabenazine
12 NDCs across 1 manufacturer|0 Generic,12 Brand
Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 3, 2017, and the first generic was approved Dec 26, 2024. In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.
Deutetrabenazine is available as 12 NDCs from 1 manufacturer (0 generic, 12 brand), with NADAC prices from $83.03 to $500.84 per EA — the most expensive product costs about 6.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
12
0G / 12B
Manufacturers
1
competing in market
Price Spread
$83.03 – $500.84
per EA
7d Activity
avg -0.2% WoW · of 12 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Teva Neuroscience, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing DEUTETRABENAZINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
AUSTEDO XR 48 MG TABLET | $500.8437 per EA | -0.23% |
AUSTEDO XR 42 MG TABLET | $498.1348 per EA | -0.35% |
AUSTEDO XR 36 MG TABLET | $416.7561 per EA | -0.43% |
AUSTEDO XR 30 MG TABLET | $332.3400 per EA | -0.21% |
AUSTEDO XR 18 MG TABLET | $251.1606 per EA | +0.15% |
AUSTEDO XR 24 MG TABLET | $250.6312 per EA | -0.08% |
AUSTEDO XR TITR(12-18-24-30 MG) | $249.3230 per EA | — |
AUSTEDO XR 12 MG TABLET | $166.7645 per EA | -0.10% |
AUSTEDO 12 MG TABLET | $125.0296 per EA | -0.16% |
AUSTEDO 9 MG TABLET | $93.9708 per EA | +0.01% |
AUSTEDO 6 MG TABLET | $83.2000 per EA | -0.12% |
AUSTEDO XR 6 MG TABLET | $83.0345 per EA | -0.68% |
Frequently Asked Questions
What is Deutetrabenazine used to treat?
Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.
When did Deutetrabenazine become available as a generic?
FDA approved the first generic Deutetrabenazine (ANDA) on Dec 26, 2024.
How much does Medicare spend on Deutetrabenazine?
In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.
How many Deutetrabenazine products are on the market?
The Deutetrabenazine drug market contains 12 NDCs from 1 manufacturer — 0 generic and 12 brand products.
What is the price range for Deutetrabenazine?
NADAC reference prices for Deutetrabenazine range from $83.0345 to $500.8437 per EA — the most expensive product costs about 6.0× the cheapest.
Which manufacturers make Deutetrabenazine?
1 manufacturer lists Deutetrabenazine in NADAC. Ranked by number of NDCs, the largest are Teva Neuroscience, Inc. (12).
How has the price of Deutetrabenazine changed recently?
Over the past 7 days, 2 Deutetrabenazine NDCs rose and 9 fell, with a market-wide average change of -0.2%.